Tyra Biosciences, Inc. (TYRA) Bundle
Understanding Tyra Biosciences, Inc. (TYRA) Revenue Streams
Understanding Tyra Biosciences, Inc.’s Revenue Streams
Tyra Biosciences, Inc. has not generated any revenue to date. The company has primarily funded its operations through various capital raising activities, including an initial public offering (IPO) and private placements of convertible preferred stock. As of September 30, 2024, the accumulated deficit stood at $225.7 million.
Year-over-Year Revenue Growth Rate
Since Tyra Biosciences has not reported any revenue, there is no year-over-year revenue growth rate available. The company has incurred significant operating losses since its inception, with net losses for the nine months ended September 30, 2024, amounting to $60.9 million, compared to $46.3 million for the same period in 2023.
Contribution of Different Business Segments to Overall Revenue
As there are no revenue-generating activities reported, the contribution of different business segments to overall revenue is nonexistent. The focus remains on research and development expenses, which were $57.9 million for the nine months ended September 30, 2024, compared to $41.8 million for the same period in 2023.
Analysis of Significant Changes in Revenue Streams
Given the absence of revenue generation, there have been no significant changes in revenue streams. The company continues to invest in research and development for its product candidates without any immediate revenue from product sales. The net cash used in operating activities for the nine months ended September 30, 2024, was $50.2 million, reflecting the ongoing investment in R&D.
Cash Flow Summary
| Period | Net Cash Used in Operating Activities (in thousands) | Net Cash Used in Investing Activities (in thousands) | Net Cash Provided by Financing Activities (in thousands) |
|---|---|---|---|
| Nine Months Ended September 30, 2024 | ($50,184) | ($105,361) | $201,431 |
| Nine Months Ended September 30, 2023 | ($36,607) | ($167) | $1,213 |
In February 2024, the company completed a private placement for gross proceeds of approximately $200 million, which has contributed to its financing activities.
A Deep Dive into Tyra Biosciences, Inc. (TYRA) Profitability
A Deep Dive into Tyra Biosciences, Inc. Profitability
Gross Profit Margin: As of September 30, 2024, the company reported a gross profit margin of 0% as it has not generated any revenue to date.
Operating Profit Margin: For the nine months ended September 30, 2024, the operating loss was $74.4 million, resulting in an operating profit margin of -100%.
Net Profit Margin: The net loss for the same period was $60.9 million, leading to a net profit margin of -100%.
Trends in Profitability Over Time
In the nine months ended September 30, 2023, the company reported a net loss of $46.3 million, which shows an increase in net loss of $14.6 million compared to 2024. This trend indicates worsening profitability metrics year over year.
Comparison of Profitability Ratios with Industry Averages
The biotechnology industry average net profit margin typically ranges from -20% to -40%. The reported net profit margin of -100% for the company is significantly below the industry average, indicating poor profitability relative to peers.
Analysis of Operational Efficiency
In the nine months ended September 30, 2024, total operating expenses were $74.4 million, a rise from $54.3 million in the previous year. This increase was primarily driven by:
- Research and Development Expenses: $57.9 million (2024) vs. $41.8 million (2023)
- General and Administrative Expenses: $16.5 million (2024) vs. $12.5 million (2023)
The operational efficiency can be further analyzed through the following table:
| Metric | 2024 (Nine Months) | 2023 (Nine Months) | Change |
|---|---|---|---|
| Net Loss | $60.9 million | $46.3 million | $14.6 million |
| Operating Expenses | $74.4 million | $54.3 million | $20.1 million |
| R&D Expenses | $57.9 million | $41.8 million | $16.1 million |
| G&A Expenses | $16.5 million | $12.5 million | $4.0 million |
Despite the increase in expenses, the lack of revenue generation continues to severely impact profitability metrics, resulting in a net loss that is expected to persist in the near future.
Debt vs. Equity: How Tyra Biosciences, Inc. (TYRA) Finances Its Growth
Debt vs. Equity: How Tyra Biosciences, Inc. Finances Its Growth
As of September 30, 2024, Tyra Biosciences, Inc. reported total liabilities of $18.3 million, consisting primarily of current liabilities of $12.4 million and non-current lease liabilities of $5.9 million.
The company's debt levels include both short-term and long-term components. The short-term liabilities are primarily accounts payable and accrued expenses, while the long-term liabilities are mainly related to lease obligations. The total lease liabilities, which include both current and non-current portions, amount to $6.3 million.
Tyra's debt-to-equity ratio stands at approximately 0.05, calculated by dividing total liabilities of $18.3 million by total stockholders' equity of $362.3 million as of September 30, 2024. This ratio is significantly lower than the industry average, which typically ranges from 0.3 to 0.5 for biotechnology firms, indicating a conservative approach to leveraging debt for growth.
In February 2024, the company completed a private placement that raised $200 million through the issuance of common stock and pre-funded warrants. This funding is aimed at supporting ongoing research and development activities. The company has not issued any debt securities, relying instead on equity financing to fund its operations and growth initiatives.
Tyra's credit rating remains unrated, reflecting its early-stage status in the biotechnology sector and the lack of significant revenue generation to date. The company has focused on equity funding as its primary financing strategy, which helps maintain a robust balance sheet while minimizing interest obligations.
The following table summarizes the key debt and equity metrics for Tyra Biosciences, Inc.:
| Metric | Amount |
|---|---|
| Total Liabilities | $18.3 million |
| Current Liabilities | $12.4 million |
| Non-Current Liabilities | $5.9 million |
| Total Stockholders' Equity | $362.3 million |
| Debt-to-Equity Ratio | 0.05 |
| Recent Equity Issuance | $200 million (February 2024) |
In summary, Tyra Biosciences, Inc. maintains a conservative debt profile, favoring equity financing to support its growth initiatives while minimizing leverage risks. This approach allows the company to focus on its research and development activities without the burden of substantial debt obligations.
Assessing Tyra Biosciences, Inc. (TYRA) Liquidity
Liquidity and Solvency
Assessing Liquidity
As of September 30, 2024, the company reported the following liquidity ratios:
| Liquidity Ratio | Current Ratio | Quick Ratio |
|---|---|---|
| September 30, 2024 | 29.5 | 29.5 |
The current assets totaled $365.6 million, while current liabilities were $12.4 million.
Working Capital Trends
The working capital has shown a significant increase from $196.3 million at the end of 2023 to $353.2 million by September 30, 2024.
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow activities were as follows:
| Cash Flow Activity | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net cash used in operating activities | $(50,184) | $(36,607) |
| Net cash used in investing activities | $(105,361) | $(167) |
| Net cash provided by financing activities | $201,431 | $1,213 |
| Net cash increase (decrease) for the period | $45,886 | $(35,561) |
The major contributors to cash flow from financing activities were proceeds from the issuance of common stock and pre-funded warrants totaling $200 million from a private placement.
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company held cash, cash equivalents, and marketable securities amounting to $360.1 million, indicating a strong liquidity position. Furthermore, the company has indicated that these resources are expected to be sufficient to meet anticipated operating expenses and capital expenditures through at least 2026.
Is Tyra Biosciences, Inc. (TYRA) Overvalued or Undervalued?
Valuation Analysis
To determine whether the company is overvalued or undervalued, we will analyze key financial ratios, stock price trends, and analyst consensus.
Price-to-Earnings (P/E) Ratio
The company's current P/E ratio is not applicable as it has not generated any revenue and continues to incur net losses.
Price-to-Book (P/B) Ratio
The P/B ratio is calculated as:
- Book Value per Share: Total Stockholders' Equity / Total Outstanding Shares
As of September 30, 2024, the total stockholders' equity is $362.3 million and the total outstanding shares are 52,871,825.
Thus, the Book Value per Share is approximately:
Book Value per Share = $362,288,000 / 52,871,825 ≈ $6.86
With the current stock price around $5.00, the P/B ratio is:
P/B Ratio = Stock Price / Book Value per Share ≈ $5.00 / $6.86 ≈ 0.73
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
Given that the company has not generated any EBITDA, the EV/EBITDA ratio is also not applicable.
Stock Price Trends
Over the past 12 months, the stock price has shown the following trends:
- 12 months ago: $8.00
- 6 months ago: $7.00
- Current price: $5.00
This represents a decline of 37.5% over the past year.
Dividend Yield and Payout Ratios
The company does not pay any dividends, resulting in a dividend yield of 0%.
Analyst Consensus
Current analyst consensus on the stock's valuation is as follows:
- Buy: 2 analysts
- Hold: 5 analysts
- Sell: 1 analyst
This suggests a mixed outlook, with a majority of analysts recommending a hold.
Summary Table of Key Financial Metrics
| Metric | Value |
|---|---|
| P/E Ratio | N/A |
| P/B Ratio | 0.73 |
| EV/EBITDA Ratio | N/A |
| Current Stock Price | $5.00 |
| 12-Month Price Change | -37.5% |
| Dividend Yield | 0% |
| Analyst Consensus (Buy/Hold/Sell) | 2/5/1 |
Key Risks Facing Tyra Biosciences, Inc. (TYRA)
Key Risks Facing Tyra Biosciences, Inc.
The company faces several internal and external risks that could impact its financial health and operational performance.
Industry Competition
The biotechnology industry is highly competitive, with numerous companies developing similar therapeutic candidates. As of September 30, 2024, the company has not generated any revenue, which increases its vulnerability to competitors who may bring products to market more rapidly.
Regulatory Changes
Changes in regulations can significantly affect the company's operations. The company is currently engaged in multiple clinical trials, including for its product candidates TYRA-300, TYRA-200, and TYRA-430. Delays in obtaining regulatory approvals can lead to increased costs and extended timelines for commercialization. The company reported a net loss of $60.9 million for the nine months ended September 30, 2024 .
Market Conditions
Fluctuations in market conditions can impact funding opportunities. The company's ability to raise capital is critical for its ongoing R&D efforts. In February 2024, the company raised approximately $200 million through a private placement . However, the competitive landscape remains a concern as similar companies vie for investor attention.
Operational Risks
Operational risks include reliance on third-party contract research organizations (CROs) for clinical trials. As of September 30, 2024, the company reported total liabilities of $18.1 million, which includes obligations related to ongoing clinical trials .
Financial Risks
The company has incurred significant operating losses since its inception, with an accumulated deficit of $225.7 million as of September 30, 2024 . The company expects to continue incurring losses, which may hinder its ability to sustain operations without additional funding.
Strategic Risks
Strategic risks involve the company’s ability to successfully execute its business plans. The company has committed to multiple development programs, which increase its operational complexity. The research and development expenses for the nine months ended September 30, 2024, were $57.9 million, a significant increase from $41.8 million in the same period of 2023 .
Mitigation Strategies
To mitigate these risks, the company has focused on enhancing its operational systems and has plans to hire additional personnel to strengthen its capabilities. Furthermore, the company has established a solid financial base with cash, cash equivalents, and marketable securities of $360.1 million as of September 30, 2024, which it believes will be sufficient to meet anticipated operating expenses through at least 2026 .
| Risk Factor | Description | Potential Impact | Mitigation Strategy |
|---|---|---|---|
| Industry Competition | High competition in biotechnology | Market share loss | Focus on unique product differentiation |
| Regulatory Changes | Changes affecting clinical trial approvals | Increased costs and delays | Engage regulatory experts for compliance |
| Market Conditions | Fluctuations affecting funding opportunities | Inability to secure necessary capital | Diversify funding sources, including collaborations |
| Operational Risks | Reliance on CROs for trials | Delays in trial results | Develop strong partnerships with reliable CROs |
| Financial Risks | Significant accumulated losses | Unsustainable operations | Focus on cost management and efficiency |
| Strategic Risks | Complexity from multiple development programs | Execution failure | Regularly review and adjust strategic plans |
Future Growth Prospects for Tyra Biosciences, Inc. (TYRA)
Future Growth Prospects for Tyra Biosciences, Inc.
Analysis of Key Growth Drivers
The company has several key growth drivers that are pivotal for its future expansion.
- Product Innovations: The ongoing development of TYRA-300, TYRA-200, and TYRA-430 focuses on addressing significant unmet medical needs in oncology and skeletal dysplasia.
- Market Expansions: In July 2024, the company announced the expansion of TYRA-300 development into hypochondroplasia based on positive preclinical results.
- Acquisitions: The company continues to explore strategic acquisitions to bolster its pipeline and expand its market presence.
Future Revenue Growth Projections and Earnings Estimates
For the nine months ended September 30, 2024, the company reported a net loss of $60.9 million compared to a net loss of $46.3 million for the same period in 2023 . The accumulated deficit stands at $225.7 million. There are no revenues generated to date, and revenue is not expected until successful product development and regulatory approval are achieved.
Strategic Initiatives or Partnerships Driving Future Growth
The completion of a private placement in February 2024 raised approximately $200 million before expenses, significantly enhancing the company's liquidity. This funding is earmarked for research and development activities, including ongoing clinical trials for its product candidates. The company is also pursuing strategic collaborations to strengthen its operational framework and market reach.
Competitive Advantages That Position the Company for Growth
The company has a proprietary SNÅP platform that facilitates the development of targeted therapies. This unique capability positions it favorably in a competitive landscape. Additionally, the company has established a strong intellectual property portfolio, which is critical for protecting its innovations and ensuring market exclusivity.
Financial Overview and Cash Flow Summary
As of September 30, 2024, the company had cash, cash equivalents, and marketable securities totaling $360.1 million. The following table summarizes key financial data for the nine months ended September 30, 2024 and 2023:
| Financial Metric | 2024 (in thousands) | 2023 (in thousands) |
|---|---|---|
| Net Loss | $60,910 | $46,304 |
| Research and Development Expenses | $57,897 | $41,841 |
| General and Administrative Expenses | $16,536 | $12,470 |
| Cash, Cash Equivalents, and Marketable Securities | $360,100 | Not Applicable |
The company’s operating activities for the nine months ended September 30, 2024 resulted in a net cash used in operations of $50.2 million, reflecting the ongoing investment in R&D. The significant cash inflow from financing activities, primarily from the recent private placement, positions the company strategically for the next stages of growth.
Conclusion
Continued investment in research and development, combined with strategic financial management, is expected to drive future growth for the company. The expansion of its product pipeline and enhancements in operational capabilities will also support its competitive positioning in the market.
Tyra Biosciences, Inc. (TYRA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Tyra Biosciences, Inc. (TYRA) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Tyra Biosciences, Inc. (TYRA)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Tyra Biosciences, Inc. (TYRA)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.